Resultados globales: 8 registros encontrados en 0.03 segundos.
Artículos, Encontrados 4 registros
Documentos de investigación, Encontrados 4 registros
Artículos Encontrados 4 registros  
1.
11 p, 3.4 MB PIVOT-12 : a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence / Eggermont, Alexander M. (Princess Máxima Center for Pediatric Oncology & University Medical Center Utrecht) ; Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G Pascale) ; Khushalani, Nikhil I. (H Lee Moffitt Cancer Center & Research Institute) ; Schadendorf, Dirk (West German Cancer Center at the University Hospital Essen) ; Boland, Genevieve (Massachusetts General Hospital (Boston)) ; Weber, Jeffrey (Perlmutter Cancer Center at NYU Langone Health) ; Lewis, Karl D. (University of Colorado Cancer Center) ; Johnson, Daniel (Ochsner Medical Center) ; Rivalland, Gareth (University of Auckland & Auckland City Hospital) ; Khattak, Adnan (Hollywood Private Hospital. Edith Cowan University) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Gogas, Helen (National & Kapodistrian University of Athens) ; Long, Georgina V. (Melanoma Institute Australia. University of Sydney. Royal North Shore & Mater Hospitals) ; Currie, Sue L. (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Chien, David (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Tagliaferri, Mary A. (Nektar Therapeutics, San Francisco, CA 94158, USA) ; Carlino, Matteo S. (Westmead & Blacktown Hospitals & Melanoma Institute Australia. University of Sydney) ; Diab, Adi (University of Texas MD Anderson Cancer Center)
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. [...]
2022 - 10.2217/fon-2021-1286
Future oncology (London, England), Vol. 18 Núm. 8 (january 2022) , p. 903-913  
2.
12 p, 1.4 MB A Longitudinal Analysis Reveals Early Activation and Late Alterations in B Cells During Primary HIV Infection in Mozambican Adults / Jiménez, Montse (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Pastor Palomo, Lucía (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Urrea, Víctor (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Rodríguez de la Concepción, María Luisa (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Parker, Erica (Faculty of Health and Medical Sciences, University of Western Australia) ; Fuente-Soro, Laura (Centro de Investigação em Saúde da Manhiça (CISM)) ; Jairoce, Chenjerai (Centro de Investigação em Saúde da Manhiça (CISM)) ; Mandomando, Inacio (Centro de Investigação em Saúde da Manhiça (CISM)) ; Carrillo, Jorge (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Naniche, Denise (Centro de Investigação em Saúde da Manhiça (CISM)) ; Blanco, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Universitat Autònoma de Barcelona
Primary HIV infection (PHI) and subsequent chronic infection alter B-cell compartment. However, longitudinal analysis defining the dynamics of B-cell alterations are still limited. We longitudinally studied B-cell subsets in individuals followed for 1 year after PHI (n = 40). [...]
2021 - 10.3389/fimmu.2020.614319
Frontiers in immunology, Vol. 11 (january 2021)  
3.
20 p, 2.2 MB Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma / Corominas Argente del Castillo, Josep (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Sapena, Victor (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Sanduzzi Zamparelli, Marco (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Millán, Cristina (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Samper, Esther (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Llarch, Neus (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Iserte, Gemma (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Torres, Ferran (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ; Da Fonseca, Leonardo G. (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Muñoz-Martínez, S (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Forner, Alejandro (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Bruix, Jordi (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Boix, Loreto (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya)) ; Reig, María (Fundació Clínic Recerca Biomèdica (Barcelona, Catalunya))
Hepatocellular carcinoma is the second cause of cancer-related death worldwide. Of those advanced-stage patients who are treated with sorafenib, those who develop early dermatologic adverse events have a better prognosis. [...]
2021 - 10.3390/cancers13030426
Cancers, Vol. 13 (january 2021)  
4.
14 p, 3.2 MB Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8 + T Cells and Evolve at the Population Level / Karimzadeh, Hadi (Department of Internal Medicine II, University Hospital Munich-Grosshadern, Munich, Germany) ; Kiraithe, Muthamia M. (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ; Oberhardt, Valerie (Faculty of Biology, University of Freiburg, Freiburg, Germany) ; Salimi Alizei, Elahe (Faculty of Chemistry and Pharmacy, University of Freiburg, Freiburg, Germany) ; Bockmann, Jan (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ; Schulze zur Wiesch, Julian (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ; Budeus, Bettina (Department of Bioinformatics, University of Duisburg-Essen, Essen, Germany) ; Hoffmann, Daniel (Department of Bioinformatics, University of Duisburg-Essen, Essen, Germany) ; Wedemeyer, Heiner (University Hospital Essen (Alemanya)) ; Cornberg, Markus (Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany) ; Krawczyk, Adalbert (Department of Infectious Diseases, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany) ; Rashidi-Alavijeh, Jassin (University Hospital Essen (Alemanya)) ; Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron) ; Casillas, Rosario (Hospital Universitari Vall d'Hebron) ; Buti, Maria (Hospital Universitari Vall d'Hebron) ; Smedile, Antonina (Department of Medical Sciences, University of Turin, Turin, Italy) ; Alavian, Seyed Moayed (Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran) ; Heinold, Andreas (University Hospital Essen (Alemanya)) ; Emmerich, Florian (Institute for Transfusion Medicine and Gene Therapy, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ; Panning, Marcus (Institute of Virology, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ; Gostick, Emma (Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom) ; Price, David A. (Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom) ; Timm, Jörg (Institute of Virology, Heinrich-Heine-University, University Hospital, Duesseldorf, Germany) ; Hofmann, Maike (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ; Raziorrouh, Bijan (Department of Internal Medicine II, University Hospital Munich-Grosshadern, Munich, Germany) ; Thimme, Robert (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ; Protzer, Ulrike (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ; Roggendorf, Michael (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ; Neumann-Haefelin, Christoph (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ; Universitat Autònoma de Barcelona
Hepatitis D virus (HDV) superinfection in patients with hepatitis B virus (HBV) is associated with rapid progression to liver cirrhosis and hepatocellular carcinoma. Treatment options are limited, and no vaccine is available. [...]
2019 - 10.1053/j.gastro.2019.02.003
Gastroenterology, Vol. 156 (may 2019) , p. 1820-1833  

Documentos de investigación Encontrados 4 registros  
1.
136 p, 6.3 MB Interrogating resistance mechanisms to PD-1 blockade therapy / Torrejon Castro, Davis Yuri ; Ribas Bruguera, Antoni, dir. ; Seoane Suárez, Joan, dir. ; Galcerán, Joan Carles, dir. ; Giralt López de Sagredo, Jordi, dir.
La immunoteràpia basada en el bloqueig del PD-1/PD-L1 ha aconseguit respostes antitumorals a llarg termini en pacients amb càncer metastàsic, però és important conèixer per què alguns pacients no responen o com altres inicialment responen i després progressen. [...]
La immunoterapia basada en el bloqueo del PD-1/ PD-L1 ha logrado respuestas antitumorales a largo plazo en pacientes con cáncer metastásico, pero es importante conocer por qué algunos pacientes no responden o cómo otros inicialmente responden y después progresan. [...]
Immunotherapy with PD-1 or PD-L1 blockade has been proved to accomplish long term anti-tumor responses in patients with metastatic cancer, but it is extremely important to understand why some patients never respond to this mode of therapy, and how some patients respond and then progress. [...]

2021  
2.
1 p, 521.3 KB Invariant Natural Killer T cell-based Immunotherapy against Cancer / Barbao Carrasco, Paula ; Universitat Autònoma de Barcelona. Facultat de Biociències
2018
Grau en Ciències Biomèdiques [832]  
3.
1 p, 1.3 MB Cancer and PD-1 receptors / Osuna Gómez, Rubén ; Castaño, A. Raul, (Ángel Raúl) dir. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Universitat Autònoma de Barcelona. Facultat de Biociències
2015
Grau en Biologia [812]  
4.
1 p, 662.5 KB Immunosupression induced by cancer cells : PD-1 and CTLA-4 pathways / Soliveras Sintes, Miriam ; Jaraquemada, Dolores, dir. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Universitat Autònoma de Barcelona. Facultat de Biociències
2014
Grau en Bioquímica [814]  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.